https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55109 Wed 10 Apr 2024 08:53:58 AEST ]]> Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54830 Fri 15 Mar 2024 11:53:47 AEDT ]]> Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51529 Fri 08 Sep 2023 12:10:33 AEST ]]>